214 related articles for article (PubMed ID: 35144967)
21. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME
Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
24. Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours.
Lassen U
Lancet Oncol; 2020 Feb; 21(2):193-194. PubMed ID: 31838008
[No Abstract] [Full Text] [Related]
25. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
[TBL] [Abstract][Full Text] [Related]
27. Evaluating entrectinib as a treatment option for non-small cell lung cancer.
Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Opin Pharmacother; 2020 Nov; 21(16):1935-1942. PubMed ID: 32736487
[TBL] [Abstract][Full Text] [Related]
28. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.
Garcia-Foncillas J; Bokemeyer C; Italiano A; Keating K; Paracha N; Fellous M; Marian M; Fillbrunn M; Gao W; Ayyagari R; Lassen U
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406565
[TBL] [Abstract][Full Text] [Related]
29. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
[TBL] [Abstract][Full Text] [Related]
30. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in
Doebele RC; Perez L; Trinh H; Martinec M; Martina R; Riehl T; Krebs MG; Meropol NJ; Wong WB; Crane G
J Comp Eff Res; 2021 Dec; 10(17):1271-1282. PubMed ID: 34427452
[No Abstract] [Full Text] [Related]
32. FDA Approval Summary: Entrectinib for the Treatment of
Marcus L; Donoghue M; Aungst S; Myers CE; Helms WS; Shen G; Zhao H; Stephens O; Keegan P; Pazdur R
Clin Cancer Res; 2021 Feb; 27(4):928-932. PubMed ID: 32967940
[TBL] [Abstract][Full Text] [Related]
33. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract][Full Text] [Related]
34. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series.
Yokota T; Yukino H; Doi M; Ohori H
Head Neck; 2023 May; 45(5):E10-E15. PubMed ID: 36924196
[TBL] [Abstract][Full Text] [Related]
35. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.
Goss G; Tsai CM; Shepherd FA; Ahn MJ; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R; Cantarini M; Johnson M; Mitsudomi T; Jänne PA; Yang JC
Ann Oncol; 2018 Mar; 29(3):687-693. PubMed ID: 29293889
[TBL] [Abstract][Full Text] [Related]
36. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Wu YL; Yang JC; Kim DW; Lu S; Zhou J; Seto T; Yang JJ; Yamamoto N; Ahn MJ; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner KD; Goto K
J Clin Oncol; 2018 May; 36(14):1405-1411. PubMed ID: 29596029
[TBL] [Abstract][Full Text] [Related]
37. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of
Liu D; Offin M; Harnicar S; Li BT; Drilon A
Ther Clin Risk Manag; 2018; 14():1247-1252. PubMed ID: 30050303
[TBL] [Abstract][Full Text] [Related]
38. Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.
Seo SW; Han DG; Choi E; Park T; Byun JH; Cho HJ; Jung IH; Yoon IS
Biomed Pharmacother; 2022 Feb; 146():112520. PubMed ID: 34902744
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Drilon A; Tan DSW; Lassen UN; Leyvraz S; Liu Y; Patel JD; Rosen L; Solomon B; Norenberg R; Dima L; Brega N; Shen L; Moreno V; Kummar S; Lin JJ
JCO Precis Oncol; 2022 Jan; 6():e2100418. PubMed ID: 35085007
[TBL] [Abstract][Full Text] [Related]
40. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
Yang JCH; Kim SW; Kim DW; Lee JS; Cho BC; Ahn JS; Lee DH; Kim TM; Goldman JW; Natale RB; Brown AP; Collins B; Chmielecki J; Vishwanathan K; Mendoza-Naranjo A; Ahn MJ
J Clin Oncol; 2020 Feb; 38(6):538-547. PubMed ID: 31809241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
